<DOC>
	<DOC>NCT01569087</DOC>
	<brief_summary>The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.</brief_summary>
	<brief_title>Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer</brief_title>
	<detailed_description>BCD-017-2 is an open-label randomized phase II clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated filgrastim empegfilgrastim (Extimia®) at a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients receiving myelosuppressive chemotherapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Signed informed consent form; Histologically verified diagnosis of stage IIb/III/IV breast cancer; Age of 1870 years inclusive; If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study; ECOG Performance Status of 0, 1 or 2, not increasing within during 2 weeks before randomization; ANC level of 1500/μL and more at the beginning of the study Platelet count of 100 000/μL and more at the beginning of the study Hemoglobin level of 90 g/l and more Creatinine level &lt;1.5 mg/dl Total bilirubin level &lt;1.5 × the upper limit of normal (ULN) ALT and/or AST levels &lt;2.5×ULN (5×ULN for patients with liver metastases); Alkaline phosphatase &lt;5×ULN; Left ventricular ejection fraction &gt;50% and more; If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 500 mg/m2 for doxorubicin or 500 mg/m2 for epirubicin; Ability of the participant to follow the protocol requirements, according to the Investigator's opinion; Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. Patient has received two or more chemotherapy regimens for the metastatic breast cancer; Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins. Pregnancy or breastfeeding; Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration; Concomitant radiotherapy (except selective radiotherapy of bone metastases); Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization; History of bone marrow/stem cell transplantation; Conditions limiting the patient's ability to follow the protocol; CTCAE grade 2/4 neuropathy HIV, HCV, HBV, T.Pallidum infection(s); Acute or active chronic infections.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>empegfilgrastim</keyword>
	<keyword>pegylated filgrastim</keyword>
	<keyword>neutropenia</keyword>
	<keyword>febrile neutropenia</keyword>
	<keyword>chemotherapy-associated neutropenia</keyword>
	<keyword>breast cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>doxorubicin</keyword>
</DOC>